Preparing for next-generation PrEP: awareness and willingness to use long-acting injectable cabotegravir among men who have sex with men and trans women across Asia

作者：H Schmidt, Curtis Chan, Polin Ung, Tiara Nisa, Jason J. Ong, Warittha Tieosapjaroen, Kimberly E. Green, Nittaya Phanuphak, Michael Cassell, Nicky Suwandi, Hua Boonyapisomparn, Midnight Poonkasetwattana, Lei Zhang, Benjamin R. Bavinton · 发表于：Sexual Health · 年份：2025 · DOI：10.1071/sh25065 · 被引用次数：2 · 研究领域：HIV/AIDS Research and Interventions、HIV-related health complications and treatments、HIV/AIDS drug development and treatment

BACKGROUND: Pre-exposure prophylaxis (PrEP) use could be accelerated by offering alternatives that overcome key barriers associated with oral PrEP. This study aimed to understand willingness and preferences for long-acting injectable cabotegravir (CAB-LA) among gay men and other men who have sex with men (MSM), and transgender women (TGW) in Asia. METHODS: An online cross-sectional survey was conducted from May to November 2022 among HIV-negative or unknown status MSM and TGW aged ≥18 years across 15 and 11 Asian countries/territories, respectively. Survey items included awareness and use of PrEP and CAB-LA, willingness to use current and emerging PrEP options, and attitudes towards CAB-LA. Descriptive statistics and logistic regression were used to analyse associations with willingness to use CAB-LA. RESULTS: Among 11,870 MSM and 980 TGW, 21.4% (n = 2448) and 32.5% (n = 295) were aware of CAB-LA, respectively, and 17.2% (n = 2036) and 16.8% (n = 165) were willing to use it. CAB-LA was the most preferred PrEP option for 3.6% (n = 400) of MSM and 6.5% (n = 61) of TGW. Awareness and willingness varied across countries/territories and populations. Key benefits of CAB-LA included HIV protection (57.8% MSM, 46.8% TGW), no need for daily pills (42.6% MSM, 31.1% TGW) and longer-term protection (38.0% MSM, 23.6% TGW). Main concerns included cost (39.6% MSM, 22.1% TGW), side-effects (37.5% MSM, 22.2% TGW), insufficient knowledge (33.3% MSM, 20.6% TGW) and pain (21.4% MSM, 24.9% TGW). ...